Tuberculin testing in HIV infection;PRUEBA DE LA TUBERCULINA EN INFECCION POR HIV

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 14, Issue 2, 1996, Pages 90-95

  Portu, José J ^a,c   Pérez, José R ^b   Arévalo, José M ^a   Aldamiz Etxebarria, Mikel ^a   Agud, José M ^a   Ayensa, Cándido ^a  

^a HOSPITAL TXAGORRITXU   (Spain)

^b Centro de Salud de Albaina   (Spain)

^c NONE   (Spain)

Author keywords

BCG vaccination; HIV infection; intravenous drug abusers; tuberculin testing

Indexed keywords

BCG VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG ABUSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION;

ADOLESCENT; ADULT; CHILD; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0029871157     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Theuer CP, Hopewell PC, Elias D, Schecter GF, Rutherford GW, Chaison RE. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990; 162: 8-12.
2. Barnes PF, Block AB, Davidson PT, Sinder DE. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1.644-1.650.
3. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
4. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1.703-1.709.
5. Alland D, Kalcut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W et al. Transmission of tuberculosis in New York city: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1.710-1.716.
6. Centers for Disease Control. Update: tuberculosis elimination-United States. MMMWR 1990; 39: 153-156.
7. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. CID 1993; 17: 968-975.
8. Robert CF, Hirschel B, Rochart T, Deglon JJ. Tuberculin skin reactivity in HIV seropositive intravenous drug addicts. N Engl J Med 1989; 321: 1.268.
9. Canessa PA, Fasano L, Lavecchia MA, Torraca A, Schiattone ML. Tuberculin skin test in asymptomatic HIV seropositive carriers. Chest 1989; 96: 1.215-1.216.
10. Consenso Nacional sobre Tuberculosis. Med Clin (Barc) 1992; 98: 24-31.
11. Aviñó Rico MJ, Hernández Aguado I, Pérez Hoyos S, García de la Hera M, Ruiz I, Bolumar Montrull F. Incidencia de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) en usuarios de drogas por vía parenteral. Med Clin (Barc) 1994; 102: 369-373.
12. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139: 337-339.
13. Bouza E, Martín-Scapa C, Bernaldo de Quirós JC, Martínez-Hernández Menárguez J, Gómez-Rodrigo J, Cosín M et al. High prevalence of tuberculosis in AIDS patients in Spain. Eur J Clin Microbiol Infect Dis 1988; 7: 785-788.
14. Centers for Disease Control. Tuberculosis an human immunodeficiency virus infection recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR 1989; 38: 236-238, 243-250.
15. Okwera A, Eriki PP, Guay LA, Ball P, Daniel TM. Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women-Uganda. MMWR 1990; 39: 638-646.
16. Programa para el control de la Tuberculosis en la Comunidad Autónoma del País Vasco. Servicio Central de Publicaciones del Gobierno Vasco. Diciembre, 1994.
17. Johnson MP, Coberly JS, Clermont HC, Chaisson RE, Davis HL, Losikoff P et al. Tubercullin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166: 194-198.
18. Graham NM, Nelson K, Solomon L, Bonds M, Rizzo RT, Scavotto J et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and seronegative intravenous drug users. JAMA 1992; 267: 369-373.
19. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119: 185-193.
20. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142: 725-735.
21. Snider DE. Bacille Calmette-Guérin vaccinations and tuberculin skin tests. JAMA 1985; 253: 3.438-3.439.
22. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146: 1.439-1.444.
23. Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect of two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994; 120: 190-198.
24. Solera J, López E, Serna E, Vergara L, Martínez-Alfaro E, Sáez L. Riesgo de tuberculosis en adictos a drogas por vía parenteral seropositivos frente al virus de la inmunodeficiencia humana. Un estudio de cohortes en comunidades de toxicómanos. Med Clin (Barc) 1993; 100: 725-729.
25. Menzies R, Vissandjee B, Mannix S, Rocher I. The booster effect in two-step tuberculin testing among those with HIV infection (abstract). Am Rev Respir Dis 1991; 143(part 2): A280.
26. Kornbluth RS, McCutchan JA. Skin test responses as predictors of tuberculous infection and of progression in HIV infected persons. Ann Intern Med 1993; 119: 241-243.
27. Moreno S. Infección por el virus de la inmunodeficiencia humana y tuberculosis: ¿quién debe recibir quimioprofilaxis? Rev Clin Esp 1994; 194: 13-14.
28. Purified Protein Derivative (PPD)-Tuberculin Anergy and HIV-infection. Guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991; 40: 27-33.
29. Pesanti E. The negative tuberculin test. Tuberculin, HIV, and anergy panels. Am J Respir Crit Care Med 1994; 149: 1.699-1.709.
30. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
31. Blatt SP, Hendrix C, Butzin C, Freeman TM, Ward WW, Hensley RE et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected. Ann Intern Med 1993; 119: 177-184.
32. Moreno S, Baraja-Etxaburu J, Bouza E, Parras F, Pérez-Tascón M, Miralles P et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119: 194-198.
33. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers: A decision analysis. JAMA 1991; 265: 2.987-2.991.
34. Sánchez Fuentes JM, Barragán Casas JM, Garcinuño Jiménez MA, Martín Casado M, Martín Marcos J. Análisis de la decisión de efectuar quimioprofilaxis con isoniazida en pacientes usuarios de drogas por via parenteral e infectados por el HIV. Rev Clin Esp 1994; 194: 81-86.